Abstract
We examined the clinical efficacy of a combination of arbekacin and fosfomycin in the treatment of various methicillin-resistant Staphylococcus aureus (MRSA) infections. The combination of arbekacin plus fosfomycin displayed 65.4% (17/26) clinical efficacy and 65.4% (17/26) bacteriological efficacy. This combination thus appeared to be an effective regimen for the treatment of MRSA infections. However, its bacteriological efficacy against concomitant Pseudomonas aeruginosa strains was only 16.7% (1/6). In addition, in 4 episodes of superinfection involving P. aeruginosa strains developed during the combination therapy.
MeSH terms
-
Aminoglycosides*
-
Anti-Bacterial Agents*
-
Dibekacin / analogs & derivatives
-
Dibekacin / therapeutic use
-
Drug Therapy, Combination / therapeutic use*
-
Fosfomycin / pharmacology
-
Fosfomycin / therapeutic use
-
Humans
-
Methicillin Resistance*
-
Microbial Sensitivity Tests
-
Pseudomonas Infections / complications
-
Pseudomonas Infections / drug therapy
-
Pseudomonas aeruginosa / drug effects
-
Staphylococcal Infections / complications
-
Staphylococcal Infections / drug therapy*
-
Staphylococcus aureus / drug effects*
-
Superinfection / drug therapy
Substances
-
Aminoglycosides
-
Anti-Bacterial Agents
-
Fosfomycin
-
Dibekacin
-
arbekacin